Kiniksa Pharmaceuticals (KNSA) AI Stock Analysis

• Market Cap: $2.49B
• Dividend Yield: N/A
• Average Volume (3M): 629.72K
• Price to Earnings (P/E): 821.2
• Beta (1Y): 0.69
• Revenue Growth: 56.18%
• EPS Growth: N/A
• Country: US
• Employees: 315
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): 0.23
• Shares Outstanding: 43,472,927
• 10 Day Avg. Volume: 482,372
• 30 Day Avg. Volume: 629,721
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 3.51
• Enterprise Value/Gross Profit: 4.54
• Enterprise Value/Ebitda: 330.78
• 1Y Price Target: $45.67
• Price Target Upside: 35.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 71 Outperform
• Price Target: $33.00 ▼(-2.22% Downside)

Kiniksa Pharmaceuticals is positioned well for future growth with strong financial performance and positive technical indicators. However, the high P/E ratio indicates potential overvaluation, while competition and trial uncertainties pose risks. The positive earnings call and corporate event announcements further bolster the outlook.

Positive Factors

Financial Performance

The company expects to remain cash flow positive on an annual basis with $308M cash available.

Market Growth

Arcalyst market share should continue to grow in earlier lines of treatment, with encouraging trends in expected utilization in 1st and 2nd recurrence points.

Product Pipeline

The company's pipeline includes promising developments such as KPL-387, which has initiated Ph2/3 study and aims for a future launch.

Negative Factors

Product Discontinuation

The company announced the discontinuation of its abiprubart development plans in Sjögren’s disease, which is viewed as a rational decision given the competitive landscape.

Strategic Focus

Abiprubart's discontinuation was a surprise, but it was noted as a strategic decision to focus on the cardiovascular pipeline.

Treatment Duration

Average upside looks limited on treatment duration, despite some room for growth.

Kiniksa Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

How the Company Makes Money

Kiniksa Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, particularly those that receive regulatory approval and enter the market. The company may also pursue partnerships and collaborations with larger pharmaceutical firms for joint development and marketing efforts, which can provide upfront payments, milestone payments, and royalties on sales. Additionally, Kiniksa may receive funding through grants or research contracts, especially for exploratory studies or clinical trials. The success of its revenue model hinges on successfully bringing its products to market and ensuring they meet the needs of healthcare providers and patients.

Kiniksa Pharmaceuticals Financial Statement Overview

Summary

Kiniksa Pharmaceuticals has shown strong financial performance with impressive revenue growth and improving profitability. While the company is still operating at a net loss, the financial trajectory is positive, supported by a strong cash flow and a stable balance sheet with low debt levels.

Income Statement

Kiniksa Pharmaceuticals has shown impressive revenue growth, with significant increases over the past few years, including a 13.7% growth from 2024 to 2025 TTM. Gross profit margin is strong at approximately 93.8% in the TTM period. However, the company is still operating at a net loss, though it has improved significantly from previous years, reducing the net loss from $43.19 million in 2024 to $2.9 million in the TTM period. This indicates a positive trajectory towards profitability.

Balance Sheet

The balance sheet shows a healthy equity position with stockholders' equity growing to $457.49 million. The debt-to-equity ratio is low at approximately 0.02, indicating low leverage and reduced financial risk. However, the company's equity ratio of 76.3% highlights stability, but the historical negative equity in 2021 and prior years is a concern, pointing to past financial instability.

Cash Flow

Cash flow analysis reveals positive trends with free cash flow growing by 72% from 2024 to the TTM period. The operating cash flow to net income ratio is exceptionally strong, indicating efficient cash management. Free cash flow to net income ratio also reflects a robust cash-generating ability. These metrics suggest strong operational efficiency and cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	529.33M	423.24M	270.26M	220.18M	38.54M	0.00
Gross Profit	409.45M	362.33M	213.74M	173.21M	29.44M	-3.81M
EBITDA	5.62M	-45.62M	-22.86M	9.77M	-154.28M	-152.42M
Net Income	4.79M	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Balance Sheet
Total Assets	661.15M	580.55M	526.32M	459.67M	232.80M	349.46M
Cash, Cash Equivalents and Short-Term Investments	307.78M	243.63M	206.37M	190.61M	182.20M	323.48M
Total Debt	9.77M	9.86M	12.26M	5.92M	6.05M	6.99M
Total Liabilities	166.14M	142.12M	87.48M	63.52M	47.76M	37.53M
Stockholders Equity	495.01M	438.44M	438.84M	-492.03M	-675.40M	-517.47M
Cash Flow
Free Cash Flow	66.49M	25.41M	13.17M	5.70M	-146.71M	-136.81M
Operating Cash Flow	66.95M	25.69M	13.30M	5.81M	-126.30M	-136.53M
Investing Cash Flow	3.52M	37.67M	-29.56M	-8.08M	128.63M	-23.44M
Financing Cash Flow	22.30M	12.27M	1.50M	2.52M	5.88M	227.09M

Kiniksa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNSA, the sentiment is Positive. The current price of 33.75 is above the 20-day moving average (MA) of 32.35, above the 50-day MA of 29.78, and above the 200-day MA of 24.07, indicating a bullish trend. The MACD of 1.22 indicates Positive momentum. The RSI at 65.78 is Neutral, neither overbought nor oversold. The STOCH value of 60.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNSA.

Kiniksa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	81 Outperform	$2.15B	12.20	27.58%	―	17.74%	59.96%
KNSA	71 Outperform	$2.49B	821.17	1.03%	―	56.18%	―
Sector *	51 Neutral	$7.82B	-0.16	-39.78%	2.19%	21.38%	-1.56%
CGON	46 Neutral	$1.95B	―	-20.95%	―	―	―
IRON	43 Neutral	$2.08B	―	-26.36%	―	―	-22.19%
BEAM	41 Neutral	$1.65B	―	-41.94%	―	-82.90%	-155.64%
CNTA	33 Underperform	$2.32B	―	-72.95%	―	117.83%	-14.45%

Kiniksa Pharmaceuticals Corporate Events

Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans

On June 5, 2025, Kiniksa Pharmaceuticals announced the design and timeline for its Phase 2/3 clinical trial of KPL-387, a monoclonal antibody for treating recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. This trial aims to evaluate the efficacy and safety of KPL-387, which is administered subcutaneously, and could potentially expand treatment options for patients with recurrent pericarditis. The announcement underscores Kiniksa’s commitment to advancing its therapeutic options and strengthening its position in the cardiovascular treatment market.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions

On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders where several proposals were voted on and passed. Key decisions included the re-election of directors across three classes, the appointment and remuneration of auditors, and the approval of various financial and governance measures. These resolutions are likely to impact the company’s governance structure and financial operations, potentially influencing its strategic direction and stakeholder relationships.

The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.